Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study

Chen Cai(University of Science and Technology of China), Changxia Shao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fan Jin(Second Affiliated Hospital of Xi'an Jiaotong University), Elisha J. Dettman(Eutropics Pharmaceuticals (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yixin Ren(Johns Hopkins University), Wei Zhou(Wuhan University), Liam C. Lee(Center for Cancer Research), Heng Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexander Gozman(Merck & Co., Inc., Rahway, NJ, USA (United States))
Future Oncology
July 16, 2024
10.1080/14796694.2024.2367957
Cited by 2

Related Papers

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
|Science|2018|2.3k
A methanotrophic archaeon couples anaerobic oxidation of methane to Fe(III) reduction
|The ISME Journal|2018|428
Anaerobic methane oxidation coupled to manganese reduction by members of the <i>Methanoperedenaceae</i>
|The ISME Journal|2020|347
Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
|EBioMedicine|2019|197
Achieving high-level nitrogen removal in mainstream by coupling anammox with denitrifying anaerobic methane oxidation in a membrane biofilm reactor
|Water Research|2017|180